𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of hepatitis B e antigen-negative patients

✍ Scribed by Chee-Kin Hui; George K. Lau

Book ID
107558460
Publisher
Springer
Year
2007
Tongue
English
Weight
138 KB
Volume
10
Category
Article
ISSN
1092-8472

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

To define virological response in hepati
To define virological response in hepatitis B e antigen–negative patients
✍ Resat Ozaras; Hakan Leblebicioglu; Cafer Eroglu 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB 👁 2 views

Hou et al. compared the efficacies of telbivudine and lamivudine in patients with hepatitis B e antigen (HBeAg)-positive and HBeAg-negative chronic hepatitis B. 1 Virological response definition in the study (Ͻ5 log 10 copies/mL) can not be applied to HBeAg-negative patients. HBeAg-negative patient

Hepatitis B e antigen–negative chronic h
Hepatitis B e antigen–negative chronic hepatitis b in Hong Kong
✍ Henry L. Y. Chan; Nancy W. Y. Leung; Munira Hussain; May L. Wong; Anna S. F. Lok 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

Hepatitis B e antigen-negative chronic hepatitis B (eϪCHB) has been reported in Asia but its prevalence and clinical significance have not been determined. The aims of this study were to determine the prevalence of eϪCHB in Hong Kong and the frequency of precore and core promoter mutations in these

Efficacy of lamivudine in patients with
Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60

Hepatitis B virus DNA prediction rules f
Hepatitis B virus DNA prediction rules for hepatitis B e antigen–negative chronic hepatitis B
✍ Jordan J. Feld; Melissa Ayers; Dahlia El-Ashry; Tony Mazzulli; Raymond Tellier; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 672 KB

After hepatitis B e antigen (HBeAg) seroconversion, hepatitis B may become inactive or progress to HBeAg-negative hepatitis with persistent or intermittent alanine aminotransferase (ALT) elevation. The aim of this study was to prospectively identify factors predictive of the clinical course in HBeAg